Here are highlights of our activities in the first half of 2020 as we work towards building a world of mental wellbeing for everyone.
News & views
Our collective understanding of mental health is increasing all the time, with advances in neuroscience, psychotherapy, psychopharmacology and digital platforms.
June 23, 2020
COMPASS Pathways Strengthens Leadership Team With Appointment of Trevor Mill as Chief Development Officer
Announcement of our new appointments to our leadership team.
April 27, 2020
COMPASS Pathways concludes successful Series B investment round
Announcement of our successful $80m Series B investment round completion.
March 25, 2020
Protecting our communities and our teams during the COVID-19 pandemic
Letter from our co-founders explaining how we have changed our work to keep people safe during this pandemic.
January 15, 2020
COMPASS Pathways granted patent covering use of its psilocybin formulation in addressing treatment-resistant depression
Article discussing the granted psilocybin patent. Featuring a comment from co-founder George Goldsmith on what this means for COMPASS Pathways.
January 03, 2020
COMPASS Pathways News | December 2019 Issue
Here are highlights of our activities in the second half of 2019 that we hope will move us closer to our goal of improving mental health care for as many as possible.
December 19, 2019
COMPASS Backgrounder
Read our backgrounder to find out more about our company and the work we are doing
December 12, 2019
COMPASS Pathways and King’s College London announce results from psilocybin study in healthy volunteers
An overview of the healthy volunteer study at Kings College London, where COMPASS Pathways COMP360 (psilocybin) was found to be well tolerated.
December 04, 2019
‘A change is in the air’ – ISAD 2019 symposium
It is estimated that 100 million people around the world suffer with depression that is not helped by existing medication. As a community, we need to do something about this. That’s why COMPASS brought together some of the world’s leading experts at the 2019 International Society of Affective Disorders (ISAD) conference in London to discuss the potential for psilocybin therapy in helping people with treatment-resistant depression.
July 23, 2019
COMPASS Pathways News | July 2019 Issue
Here are highlights of our activities in the first half of 2019 that we hope will move us closer to our goal of improving mental health care for as many as possible.
December 19, 2018
COMPASS Pathways News | December 2018 Issue
As 2018 draws to a close, we reflect on another busy year and share our highlights of the last few months with you.
November 11, 2018
Navigating mental health: COMPASS Pathways’ psilocybin research programme
Article written for the MAPS Bulletin Winter 2018. By Ekaterina Malievskaia, MD, MSc
October 23, 2018
COMPASS Pathways receives FDA Breakthrough Therapy designation for psilocybin therapy for treatment-resistant depression
COMPASS Pathways, a life sciences company dedicated to accelerating patient access to evidence-based innovation in mental health ...
July 17, 2018
COMPASS Pathways News | July 2018 Issue
This is the second of regular newsletters from COMPASS, highlighting recent and forthcoming events and developments that are relevant to us, our partners and healthcare system stakeholders.
December 19, 2017
COMPASS Pathways News | December 2017 Issue
The holiday season is approaching, and as we begin dreaming of festive treats and spending the holidays cocooned in thick duvets with a cup of hot chocolate in hand, I would like to reflect on our journey this past year and share a few 2017 highlights.